Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP.
Adv Ther. 2022 Oct 28. doi: 10.1007/s12325-022-02302-2. Epub ahead of print.
Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
Negri S, De Ponti E, Sina FP, Sala E, Dell'Oro C, Roversi G, Lazzarin S, Delle Marchette M, Inzoli A, Toso C, Fumagalli S, Campanella M, Kotsopoulos J, Fruscio R.
Mol Genet Genomic Med. 2022 Oct 28:e2071. doi: 10.1002/mgg3.2071. Epub ahead of print.
APC germline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?
Vibert R, Le Gall J, Buecher B, Mouret-Fourme E, Bataillon G, Becette V, Trabelsi-Grati O, Moncoutier V, Dehainault C, Carriere J, Schwartz M, Suybeng V, Bieche I, Colas C, Vincent-Salomon A, Stoppa-Lyonnet D, Golmard L.
J Med Genet. 2022 Oct 21:jmedgenet-2022-108467. doi: 10.1136/jmg-2022-108467. Epub ahead of print.
Association of Treatment Response with Clinicopathological Characteristics in Female Breast Cancer Patients: Genomic Insights for Future Implementation of Personalized Medicine in Egypt.
Nakhla S, Elhameed AA, Ali IM, Elnaggar M, Hassan R, Yousef M, Adel K, Saleh W, Gaber M, Kotze MJ, El-Sharkawy RM.
Front Genet. 2022 Oct 12;12:990669. doi: 10.3389/fgene.2022.990669.